Online inquiry

IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14563MR)

This product GTTS-WQ14563MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), B cell acute lymphoblastic leukemia (B cell ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14563MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7328MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ5541MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ3370MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ1262MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-414
GTTS-WQ5621MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ3608MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ9417MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Iomab-B
GTTS-WQ6565MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DC-1630423
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW